Introduction
============

For patients with glaucoma or ocular hypertension (OHT), early management of intraocular pressure (IOP) to reach a low target IOP is recommended to preserve visual function.[@b1-opth-9-1605]--[@b6-opth-9-1605] When single agents are not sufficient to achieve target IOP, fixed combinations of IOP-lowering medications such as bimatoprost 0.03%/timolol 0.5% (FCBT, Ganfort^®^; Allergan, Inc., Irvine, CA, USA)[@b7-opth-9-1605] are preferred over concurrent administration of multiple medications.[@b2-opth-9-1605],[@b8-opth-9-1605] Although a recent meta-analysis of studies evaluating fixed and unfixed combinations of IOP-lowering ophthalmic solutions concluded that unfixed combinations provide greater IOP lowering, the heterogeneity coefficient was \>50% (*I*^2^=52%), indicating that the effect was likely owing to substantial variations in study design.[@b9-opth-9-1605]

Once-daily FCBT is effective and generally well tolerated in treatment-naïve patients as well as in those with inadequate IOP lowering with monotherapy.[@b3-opth-9-1605],[@b4-opth-9-1605],[@b10-opth-9-1605]--[@b12-opth-9-1605] FCBT eyedrops contain benzalkonium chloride (BAK) as a preservative[@b7-opth-9-1605] and although most patients tolerate BAK, its use may not be favorable in some patients with severe ocular surface disease or sensitivity to preservative (despite the lack of confirmatory clinical evidence).[@b13-opth-9-1605]--[@b15-opth-9-1605] Single-dose, preservative-free formulations of topical IOP-lowering medications are thus being developed as alternatives for patients with sensitivity/allergy to BAK. A Phase III study, designed to compare the efficacy of FCBT with a new preservative-free formulation of fixed-combination bimatoprost 0.03%/timolol 0.5% (FCBT PF), showed that although statistically equivalent, FCBT PF produced numerically greater IOP reduction.[@b16-opth-9-1605] To confirm this finding and investigate whether the difference in efficacy between FCBT PF and FCBT might be due to the treatment status at study entry (ie, treatment-naïve or previously treated), we conducted a post hoc subgroup analysis to assess the IOP-lowering efficacy of FCBT PF and FCBT in treatment-naïve vs previously treated patients.

Methods
=======

As reported, a randomized, double-masked, active-controlled, 12-week, Phase III study (NCT01177098) was conducted between October 31, 2010 and February 21, 2012, in 55 centers worldwide.[@b16-opth-9-1605] The study was approved by an institutional review board or independent ethics committee at each site. Written informed consent was obtained from each patient.

Participants
------------

Eligible subjects were aged ≥18 years and had glaucoma or OHT that was either treatment-naïve (with IOP \>24 mmHg in at least one eye) or inadequately controlled with current therapy (ie, IOP \>18 mmHg in at least one eye). Following washout of previous treatment (if applicable), patients were required to have an IOP of 22--30 mmHg in each eye, with ≤3 mmHg asymmetry between eyes. The washout period was 4 days for cholinergic agonists and carbonic anhydrase inhibitors, 2 weeks for α2-adrenergic agonists, and 4 weeks for β-adrenergic antagonists, prostaglandin analogs, and combination products. A best-corrected visual acuity score ≥20/100 was also required at baseline.

Exclusion criteria included uncontrolled, systemic disease; known allergy, sensitivity, or contraindication to any components of the study medications; introduction or anticipated change of chronic medications that may significantly impact IOP (eg, systemic β-blockers) starting 2 months before the screening visit through the final visit; history of intraocular or ocular anterior segment surgery in either eye within 6 months of study initiation; ocular surface disease symptoms (eg, irritation or hyperemia ≥+0.5 per the standard 5-point scoring system);[@b17-opth-9-1605]--[@b19-opth-9-1605] functionally significant visual field loss (per the investigator's opinion) or evidence of progressive visual field loss; corneal thickness \<500 µm and \>600 µm; history of severe ocular trauma, uveitis, ocular neoplasm, or herpetic disease in either eye; and anticipated need of contact lenses in either eye during the study period.

Treatments and assessments
--------------------------

Randomized patients were provided with the study medication in kits containing identical single-use containers (for masking) and were instructed to administer one drop in each eye every morning between 7 am and 9 am until study completion. IOP was measured using a slit lamp-mounted Goldmann applanation tonometer at 8 am, 10 am, and 4 pm at baseline, and at weeks 2, 6, and 12. Two consecutive measurements of each eye were taken at the same time of the day throughout the study, using a two-person reading method. If the measurements differed by ≤1 mmHg, the average of both IOP readings was used. Otherwise, a third measurement was taken, and IOP for the given eye was the median of all three readings. Safety assessments included adverse events (AEs), biomicroscopy, and other ophthalmic evaluations.[@b17-opth-9-1605]--[@b19-opth-9-1605]

Outcome measurements and statistical analyses
---------------------------------------------

In the primary study, an average eye analysis was performed to test for equivalence of FCBT PF and FCBT, using the intent-to-treat (ITT) population. Treatments were compared in an analysis of variance model using treatment and investigator as fixed effects. The last observation carried forward (LOCF) method was used to impute the missing data. A two-sided 95% confidence interval (CI) was determined using an estimated treatment difference based on least-square means, and FCBT PF was declared equivalent to FCBT if the upper and lower limits of the 95% CI were ≤1.5 mmHg and ≥−1.5 mmHg at all time points, and ≤1.0 mmHg and ≥−1.0 mmHg at the majority of time points, respectively.

In this post hoc analysis, the IOP-lowering efficacy of FCBT PF was evaluated in treatment-naïve (N=50) vs previously treated washed-out patients (N=228) by comparing the two subgroups with respect to the change from baseline in average eye IOP (ITT population). An analysis of covariance model with treatment and investigator as fixed effects, and baseline average eye IOP, age, glaucoma diagnosis, and baseline average eye corneal thickness as covariates was used. The difference (treatment-naïve − previously treated) was determined based on the least-square means from the model and deemed significant if the *P*-value was ≤0.05. Missing values were imputed using the LOCF method. Analyses were performed using SAS^®^ 9.3 software (SAS Institute Inc., Cary, NC, USA).

Results
=======

A total of 561 patients were randomized to FCBT PF (N=278) or FCBT (N=283) ([Figure 1](#f1-opth-9-1605){ref-type="fig"}). Demographic and baseline characteristics were not statistically different between both groups.[@b16-opth-9-1605]

Based on a priori defined criteria, FCBT PF demonstrated equivalence to FCBT in IOP lowering, with differences in IOP lowering between the treatments consistently favoring FCBT PF.[@b16-opth-9-1605] The upper limit of the 95% CI for the treatment difference did not exceed 0.36, and the lower limit was never less than −0.82 mmHg at any time point. Moreover, FCBT PF had a safety/AE profile similar to that of FCBT.[@b16-opth-9-1605]

Post hoc subgroup analysis
--------------------------

In the post hoc analysis, statistically significant differences in mean age and diagnosis (glaucoma or OHT) were found between the treatment-naïve and previously treated subgroups ([Table 1](#t1-opth-9-1605){ref-type="table"}). Within the treatment-naïve and previously treated subgroups, however, baseline characteristics were similar, whether receiving FCBT or FCBT PF. Moreover, baseline IOP, age, disease diagnosis (glaucoma or OHT), and corneal thickness were found to have a significant effect on IOP lowering (*P*≤0.05) ([Table 1](#t1-opth-9-1605){ref-type="table"}). After adjusting for these factors, FCBT PF demonstrated a 0.8--1.7 mmHg greater IOP-lowering effect in treatment-naïve patients than in previously treated patients, and these differences were statistically significant at seven of nine time points (*P*\<0.05; [Figure 2](#f2-opth-9-1605){ref-type="fig"}). Mean changes from baseline IOP ranged from −8.7 mmHg to −9.8 mmHg in treatment-naïve patients, compared with −7.3 mmHg to −8.5 mmHg in previously treated patients. Numerical differences in IOP lowering from baseline were also observed between treatment-naïve and previously treated patients who received FCBT but were not statistically significant ([Figure 3](#f3-opth-9-1605){ref-type="fig"}).

The overall incidence of AEs was not significantly different in treatment-naïve and previously treated patients who received FCBT. For patients who received FCBT PF, only the incidence of eye pain and influenza was higher in treatment-naïve patients (*P*=0.022 and *P*=0.032, respectively) than in previously treated patients ([Table 2](#t2-opth-9-1605){ref-type="table"}).

Discussion
==========

FCBT PF provides an effective IOP-lowering alternative for patients who are inadequately controlled on monotherapy and/or are sensitive to preservatives.[@b16-opth-9-1605] While combination therapies are typically used for patients inadequately managed on monotherapy, FCBT has also been shown to be effective in treatment-naïve patients.[@b20-opth-9-1605] The results of this post hoc analysis similarly demonstrated the efficacy of FCBT PF in lowering IOP in patients with glaucoma or OHT who were treatment-naïve.

In this 12-week study, FCBT PF produced greater IOP lowering effect in treatment-naïve patients than in previously treated patients, and the difference was statistically significant at seven of nine time points. The differences in baseline IOP, age, and diagnosis (glaucoma or OHT) observed between treatment-naïve and previously treated patients were not unexpected. While the difference in corneal thickness between treatment-naïve and previously treated patients was statistically significant (in FCBT-treated patients), the actual value was small and unlikely to be clinically meaningful. Although such factors could affect the IOP reduction, FCBT PF retained a statistically significantly greater IOP-lowering effect in treatment-naïve patients than in previously treated patients after adjusting for these factors.

The reason for the more favorable IOP-lowering effect of FCBT PF in the primary study is unknown. One hypothesis is the effect of BAK removal in optimizing the efficacy of FCBT.[@b21-opth-9-1605],[@b22-opth-9-1605] A recently presented retrospective analysis of the dose response to timolol found that the optimal IOP-lowering dose of timolol is between 0.25% and 0.5%, suggesting that removal of BAK may have decreased timolol exposure at the target site and thereby improved its efficacy.[@b22-opth-9-1605]

A potential explanation for the significantly greater IOP-lowering effect of FCBT PF in treatment-naïve patients than in previously treated patients is reduced responsiveness caused by prior treatment with IOP-lowering medications. Reports of tachyphylaxis associated with a prostamide/prostaglandin analog, such as bimatoprost and travoprost, or carbonic anhydrase inhibitor, such as brinzolamide (the ocular hypotensives most frequently used by the study population prior to enrollment),[@b15-opth-9-1605] have not been found in the literature, although tachyphylaxis has been reported with the use of latanoprost in a small sample of 14 patients treated for 1 year.[@b23-opth-9-1605] On the other hand, there have been reports of development of a short-term and long-term lack of responsiveness to timolol in patients with glaucoma.[@b24-opth-9-1605]--[@b28-opth-9-1605] β-Adrenergic ligands can lead to changes in density of β-adrenergic receptors on the cell surface,[@b29-opth-9-1605],[@b30-opth-9-1605] potentially altering responsiveness to these agents. Of note though, more recent studies have failed to detect evidence of tachyphylaxis over 12 months with twice-daily use of timolol.[@b31-opth-9-1605] The use of systemic β-blockers could also have accounted for the differences in IOP reduction in this study; however, the percentage of treatment-naïve and previously treated patients who were taking systemic β-blockers was similar in the FCBT PF (14.0% vs 19.3%) and FCBT groups (13.3% vs 14.0%), respectively. In contrast, FCBT was numerically but not statistically more effective in treatment-naïve patients, compared with previously treated patients. This could be due to the removal of BAK in FCBT PF optimizing the efficacy of timolol (as inferred earlier in the Discussion section), resulting in further differentiation of the effect between treatment-naïve and previously treated patients who received FCBT PF. The underlying cause for the difference in IOP-lowering response between treatment-naïve and previously treated patients thus requires further investigation in larger groups of patients.

Limitations of the post hoc analysis include its retrospective nature and the lower number of treatment-naïve patients, compared with those previously treated. In addition, the safety outcomes in patients receiving FCBT PF may not have reflected an increased tolerability since previously treated patients with known BAK sensitivity were selected out from the study at screening. Therefore, further evaluation of FCBT PF in a population of patients with sensitivity to BAK would be warranted. The lack of information about the duration of prior treatments (as well as the type of preservative included in those) should also be considered as it might have accounted -- at least partly -- for the IOP-lowering differences induced by FCBT PF in treatment-naïve and previously treated patients. Overall though FCBT PF had a favorable IOP-lowering effect over 12 weeks in treatment-naïve patients, compared with FCBT, thus representing an effective IOP-lowering alternative for patients who are allergic or sensitive to preservatives.
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###### 

Patients' baseline characteristics that affect IOP lowering in the post hoc analysis

  Characteristic                                                          FCBT PF         FCBT                                                      
  ----------------------------------------------------------------------- --------------- --------------- --------- --------------- --------------- ---------
  Mean age, y (range)                                                     59.0 (20--81)   64.6 (29--85)   \<0.001   58.2 (29--81)   65.0 (23--86)   \<0.001
  Diagnosis, N (%)                                                                                        \<0.001                                   \<0.001
   OHT                                                                    22 (44.0)       33 (14.5)                 23 (38.3)       32 (14.5)       
   Glaucoma                                                               27 (54.0)       193 (84.6)                36 (60.0)       183 (82.8)      
   1 diagnosis in each eye                                                1 (2.0)         2 (0.9)                   1 (1.7)         6 (2.7)         
  Corneal thickness, µm (SD)[b](#tfn2-opth-9-1605){ref-type="table-fn"}   556 (25)        551 (27)        0.484     564 (24)        553 (28)        0.007
  IOP, mmHg (SD)[b](#tfn2-opth-9-1605){ref-type="table-fn"}                                                                                         
   Hour 0                                                                 25.4 (1.9)      24.8 (2.2)      0.66      25.1 (1.8)      24.8 (2.2)      0.62
   Hour 2                                                                 25.1 (2.0)      24.1 (2.6)      0.40      24.5 (2.0)      24.2 (2.5)      0.79
   Hour 8                                                                 23.9 (2.2)      23.3 (3.0)      0.19      23.7 (2.2)      23.3 (2.8)      0.68

**Notes:**

Comparison of treatment-naïve vs previously treated patients.

Mean average eye IOP.

**Abbreviations:** IOP, intraocular pressure; FCBT PF, preservative-free formulation of fixed-combination bimatoprost 0.03%/timolol 0.5%; FCBT, fixed-combination bimatoprost 0.03%/timolol 0.5%; y, years; OHT, ocular hypertension; SD, standard deviation.

###### 

Adverse events in treatment-naïve and previously treated patients

  Adverse event, N (%)     FCBT PF                                              FCBT                    
  ------------------------ ---------------------------------------------------- ----------- ----------- -----------
  Conjunctival hyperemia   11 (22.0)                                            48 (21.1)   10 (16.7)   45 (20.5)
  Eye pruritus             4 (8.0)                                              8 (3.5)     2 (3.3)     3 (1.4)
  Skin hyperpigmentation   4 (8.0)                                              7 (3.1)     2 (3.3)     2 (0.9)
  Dry eye                  4 (8.0)                                              5 (2.2)     2 (3.3)     1 (0.5)
  Eye pain                 4 (8.0)[a](#tfn5-opth-9-1605){ref-type="table-fn"}   3 (1.3)     1 (1.7)     4 (1.8)
  Punctate keratitis       2 (4.0)                                              6 (2.6)     2 (3.3)     5 (2.3)
  Growth of eyelashes      2 (4.0)                                              2 (0.9)     4 (6.7)     4 (1.8)
  Influenza                2 (4.0)[a](#tfn5-opth-9-1605){ref-type="table-fn"}   0           0           0
  Eye irritation           1 (2.0)                                              5 (2.2)     2 (3.3)     3 (1.4)
  Foreign body sensation   1 (2.0)                                              5 (2.2)     2 (3.3)     4 (1.8)

**Notes:** All adverse events with an incidence \>2.0% in either subgroups are reported.

*P*≤0.032 vs previously treated patients.

**Abbreviations:** FCBT PF, preservative-free formulation of fixed-combination bimatoprost 0.03%/timolol 0.5%; FCBT, fixed-combination bimatoprost 0.03%/timolol 0.5%.
